Trial · NCT01306045
Participant flow51
How many started, completed or left each group, period by period.
1 to 20 of 51
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Met General Eligibility Criteria | STARTED | Participants With Non-Small Cell Lung Cancer | 481 | |
| Met General Eligibility Criteria | STARTED | Participants With Small Cell Lung Cancer | 68 | |
| Met General Eligibility Criteria | STARTED | Participants With Thymic Malignancies | 98 | |
| Met General Eligibility Criteria | Had EGFR Mutations | Participants With Non-Small Cell Lung Cancer | 88 | |
| Met General Eligibility Criteria | Had EGFR Mutations | Participants With Small Cell Lung Cancer | 1 | |
| Met General Eligibility Criteria | Had EGFR Mutations | Participants With Thymic Malignancies | 1 | |
| Met General Eligibility Criteria | Had KRAS, HRAS, NRAS, or BRAF Mutations | Participants With Non-Small Cell Lung Cancer | 103 | |
| Met General Eligibility Criteria | Had KRAS, HRAS, NRAS, or BRAF Mutations | Participants With Small Cell Lung Cancer | 5 | |
| Met General Eligibility Criteria | Had KRAS, HRAS, NRAS, or BRAF Mutations | Participants With Thymic Malignancies | 2 | |
| Met General Eligibility Criteria | Had PTEN, Akt1, or PIK3CA Abnormalities | Participants With Non-Small Cell Lung Cancer | 22 | |
| Met General Eligibility Criteria | Had PTEN, Akt1, or PIK3CA Abnormalities | Participants With Small Cell Lung Cancer | 7 | |
| Met General Eligibility Criteria | Had PTEN, Akt1, or PIK3CA Abnormalities | Participants With Thymic Malignancies | 2 | |
| Met General Eligibility Criteria | Had ERBB2 Mutations or Amplifications | Participants With Non-Small Cell Lung Cancer | 13 | |
| Met General Eligibility Criteria | Had ERBB2 Mutations or Amplifications | Participants With Small Cell Lung Cancer | 1 | |
| Met General Eligibility Criteria | Had ERBB2 Mutations or Amplifications | Participants With Thymic Malignancies | 1 | |
| Met General Eligibility Criteria | Had KIT or PDGFRA Mutations or Amplifications | Participants With Non-Small Cell Lung Cancer | 5 | |
| Met General Eligibility Criteria | Had KIT or PDGFRA Mutations or Amplifications | Participants With Small Cell Lung Cancer | 1 | |
| Met General Eligibility Criteria | Had KIT or PDGFRA Mutations or Amplifications | Participants With Thymic Malignancies | 5 | |
| Met General Eligibility Criteria | Enrolled Onto Treatment Arm | Participants With Non-Small Cell Lung Cancer | 38 | |
| Met General Eligibility Criteria | Enrolled Onto Treatment Arm | Participants With Small Cell Lung Cancer | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01306045/flow